Xellia Completes Budapest Facility Expansion

Aug 24, 2017
By BioPharm International Editors

Xellia Pharmaceuticals, which focuses on providing anti-infective APIs and finished drugs, has completed the expansion of its new $13-million centralized laboratory services building at its Budapest manufacturing site, expanding its product stability and release testing capabilities for APIs and finished drugs produced across the company’s sites, including those in the United States, China, and Denmark, the company announced in a press release posted on Aug. 22, 2017. The new facilities were opened in a formal ceremony on Aug. 8, 2017.

The 3000-m2, multistory building accommodates microbiology and chemical analytical laboratories, a product stability center, and administrative offices. It is located next to Xellia’s current API manufacturing plant, which employs 250 people. The expansion created more than 40 new roles within the quality team and, with recruitment still ongoing, the company plans to increase the team at the centralized laboratory services operation to approximately 80 employees by 2019. 

“As anti-microbial drug resistance continues to pose a very real international threat, our work in the production of specialty anti-infectives is more important than ever,” said Carl-Åke Carlsson, Xellia’s CEO, in the press release. “Many of the medicines that we manufacture are antibiotics of last resort, used to treat patients when all other treatments have failed. As a world-leading manufacturer we are committed to providing a high quality, secure, and safe product supply.”

Source: Xellia 

native1_300x100
lorem ipsum